1 / 65

National Clinical Guidelines: An Update in Coronary Artery Disease

National Clinical Guidelines: An Update in Coronary Artery Disease. June 19, 2011 Joseph P. Bryant, Pharm.D., BCPS LCDR, U.S. Public Health Service Indian Health Service . Objectives. Review Updated Guidelines for the Management of Coronary Artery Disease (CAD)

fox
Download Presentation

National Clinical Guidelines: An Update in Coronary Artery Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. National Clinical Guidelines: An Update in Coronary Artery Disease June 19, 2011 Joseph P. Bryant, Pharm.D., BCPS LCDR, U.S. Public Health Service Indian Health Service

  2. Objectives • Review Updated Guidelines for the Management of Coronary Artery Disease (CAD) • ACC/AHA STEMI and NSTEMI Guidelines • Review Key Drug Interactions Impacting CAD • Proton Pump Inhibitors (PPIs) & Clopidogrel • Review important FDA guidance Impacting CAD • Drug Safety Communication – Simvastatin 80mg

  3. Background Information

  4. Importance of Managing Heart Disease • Cardiovascular (CV) disease is the leading cause of hospitalizations in the U.S. at ~ 6.2 million discharges per year • Is a major contributor to morbidity, morality & healthcare cost • Each year there are more than 1.3 million myocardial infarctions (MIs) • An estimated 2200 Americans die from CV diseases per day • In 2010, the cost of Heart Disease in the U.S. was ~ $316.4 billion

  5. STEMI vs. NSTEMI • Classification: • STEMI – ST segment elevation MI • ST segmented elevated on ECG • NSTEMI – Non-ST segment elevation MI • ST segment not elevated, but rather may see ST segment depression, T-wave inversion or no change on ECG • STEMI • Are at the greatest risk of death and reinfarction • Initiate reperfusion therapy as soon as possible • NSTEMI • Initiate therapy based upon risk stratification

  6. Risk Stratification in NSTEMI • Thrombosis in Myocardial Infarction (TIMI) Risk Score • Based upon clinical presentation & medical history • Medical Presentation: • ST-segment depression (0.5mm or greater) • Two or more episodes of chest discomfort with past 24 hours • Positive biochemical markers (troponin I or T)

  7. Risk Stratification in NSTEMI • Patient History: • Age 65 years or older • Three or more of the following risk factors for CAD: • Hypercholesterolemia • Hypertension • Diabetes Mellitus • Smoking • Family history of premature CHD • Known CAD (50% or greater stenosis of a coronary artery) • Use of aspirin with the past 7 days

  8. Risk Stratification in NSTEMI • Score Assessment: • 1 point is assigned for each of the 4 medical history & clinical presentation factors • Total number of points are calculated together which assigns the patient’s risk for the composite end point of death, MI or urgent need for revascularization within 14 days • High risk: 5-7 points • Medium risk: 3-4 points • Low risk: 0-2 points

  9. Levels of Recommendations • Class I: Evidence and/or general agreement that procedure or treatment is useful & effective • Class II: Evidence is conflicting and/or there is divergence of opinion regarding the usefulness or efficacy of the procedure or treatment • Class IIa: Recommendations and the weight of evidence or opinion is in favor of the procedure or treatment • Class IIb: Recommendations and the weight of evidence are less established be evidence or opinion • Class III: Recommendation that the treatment or procedure should not be completed • Either not useful or may be harmful

  10. Objectives • Review Updated Guidelines for the Management of Coronary Artery Disease (CAD) • ACC/AHA STEMI and NSTEMI Guidelines • Review Key Drug Interactions Impacting CAD • Proton Pump Inhibitors (PPIs) & Clopidogrel • Review important FDA guidance Impacting CAD • Drug Safety Communication – Simvastatin 80mg

  11. STEMI Treatment Algorithm

  12. NSTEMI Treatment Algorithm

  13. NSTEMI Treatment Algorithm

  14. Therapeutic Treatment Options

  15. Platelet Activation • Platelets adhere to the vascular injury • ADP is released from the platelet • ADP binds to P2Y12 receptors helping activate platelets • Activated platelets expose glycoprotein IIb/IIIa • Exposed GPIIb/IIIa crosslink with fibrin to form platelet aggregates • Aggregates embolize and cause obstructions leading to myocardial ischemia and infarction.

  16. Clotting Cascade

  17. Aspirin Therapy • MOA: Thromboxane A2 Inhibitor • Recommendation: Class I – STEMI or NSTEMI • Contraindications: • Hypersensitivity, active bleed or severe risk for bleeding • Dosing & Duration of Therapy: • Day 1 (regardless of therapy): 160-325mg • Non-PCI: 75-162mg on day 2 and continue definitely • PCI: Based upon type of stent • Bare metal: 162-325mg for 30 days; then 75-162mg daily • Sirolimus-eluting: 162-325mg for 3months; then 75-162mg daily • Paclitaxel-eluting: 16 -325mg for 6months; then 75-162mg daily • Continue therapy indefinitely

  18. Thienopyridine Antiplatelets • MOA: • Irreversibly bind to P2Y12 class of ADP receptors, which prevents GPIIb/IIIa receptor complex and thus reducing platelet aggregation • Effect is for the life of the platelet ~ 7-10 days • FDA Approved Products: • Ticlopidine (Ticlid®) • Clopidogrel (Plavix®) • Prasugrel (Effient®)

  19. Clopidogrel (Plavix®) • Contraindications: • Hypersensitivity, active bleeding or severe bleeding risk • Warnings: • Diminished antiplatelet effect due to impaired CYP2C19 function • General risk of bleeding • Patients with recent TIA or stroke • Thrombotic thrombocytopenic purpura • Consider potential PPI interaction • Recommendations: Class I • STEMI & NSTEMI (with or without PCI) with aspirin • Patients with aspirin hypersensitivity • Discontinue 5 days before elective CABG surgery

  20. Clopidogrel (Plavix®) • Dosing: • STEMI • Patients receiving fibrinolytic or no reperfusion • 300mg on Day 1; followed by 75mg daily • Patients receiving PCI: • 300-600mg on Day 1; followed by 75mg daily • NSTEMI: • PCI or Non-PCI: • 300-600mg on Day 1, followed by 75mg daily • Duration of Therapy: • Continue for minimum of 12 months (Class I) and up to 15 months if necessary (Class IIb) • Continue indefinitely in patients with aspirin allergy

  21. Prasugrel (Effient®) • Contraindications: • Hypersensitivity, active bleeding, prior stroke/TIA • Warnings: • General risk of bleeding • Age >75* • CABG or other surgical procedure • Body weight <60kg • Propensity to bleed • Medications that increase risk of bleeding • Thrombotic thrombocytopenia purpura • Recommendations: Class I • STEMI & NSTEMI with PCI in conjunction with aspirin • Discontinue 7 days before elective CABG surgery

  22. Prasugrel (Effient®) • Dosing: • Patients >60kg: 60mg day 1, then 10mg daily • Patients <60kg: 60mg day 1, then 5mg daily • Duration of Therapy: • Continue for a minimum of 12 months (Class I) and up to 15 months if necessary (Class IIb) • Miscellaneous: • Avoid in patients greater than 75 years of age unless patient has Diabetes Mellitus or history of an MI • Pivotal trial for FDA approval –TRITON-TIMI

  23. TRITON-TIMI 38 Study • Study design: • MC, International, DB, PG • Patient population: • 13,608 patients with moderate to high-risk ACS who received PCI • Treatment Arms: • Prasugrel 60mg loading dose then 10mg maintenance dose or • Clopidogrel 300mg loading dose and 75mg maintenance dose for 6-15 months • Duration of Therapy: 6-15 months • Both arms where on aspirin daily • Primary outcome: • Death from CV causes, nonfatal MI or nonfatal stroke • Secondary endpoints: • Composite of CV death, nonfatal MI, nonfatal stroke or urgent target revascularization

  24. TRITON-TIMI 38 • Pts were followed for a median of 14.5 months • 74% presented with UA/NSTEMI and 26% with STEMI • Sub-Analysis Groups • Diabetes Mellitus • STEMI • Hx of TIA/Stroke

  25. TRITON-TIMI Results Primary Endpoint *Post-Hoc analysis

  26. TRITON-TIMI Sub-Analysis

  27. TRITON-TIMI Sub-Analysis *p<0.05, +non-fatal and fatal MI

  28. TRITON-TIMI 38 • Safety Endpoints – non-CABG related TIMI major and life-threatening bleeding and TIMI major and minor bleeding, CABG related TIMI fatal and life-threatening bleeding

  29. TRITON-TIMI 38 *non-CABG

  30. TRITON-TIMI 38 Conclusions • Dual-antiplatelet therapy with aspirin and prasugrel showed significantly reduced rates of death from CV causes, nonfatal MI or nonfatal stroke versus and stent thrombosis then clopidogrel/aspirin. • Prasugrel/aspirin showed an increased risk of major bleeding ,including fatal bleeding versus clopidogrel/aspirin. • Patients who may not benefit from prasugrel are those >75 years old, weight <60kg, prior hx of TIA/stroke • Patients who may benefit are those with DM or STEMI

  31. Unfractionated Heparin • MOA: Potentiates the inhibitory action of Antithrombin III (heparin cofactor) which in turn inhibits clotting factors XIIa, XIa, IXa, Xa & IIa • Contraindications: Active bleed, h/0 of heparin-induced thrombocytopenia (HIT) severe bleeding risk & recent stroke • Recommendations: • STEMI: Patients undergoing PCI or fibrinolytic therapy (Class I) • NSTEMI: Patients undergoing PCI (Class I) or conservative therapy (non-PCI) • Dosing: • Can vary, but typical dose is 60 units/kg IV bolus (max of 4000 units) followed by IV infusion of 12 units/kg/hour (max of 1000 units) • Maintain aPTT at 1.5-2 times control

  32. Enoxaparin (Lovenox®) • MOA: • Potentiates the inhibitory action of Antithrombin III (heparin cofactor) • Possesses higher anti-factor Xa to anti-factor IIa activity (3:1) than heparin • Contraindications: Active bleed, h/0 HIT, severe bleeding risk & recent stroke • Recommendations: • STEMI: Patients with PCI (Class IIa) or fibrinolytic therapy (Class I) • NSTEMI: Patients with PCI (Class IIa) or conservative therapy (non-PCI) (Class IIb) • Dosing: • CrCl > 30 mL/minute: 1mg/kg every 12 hours • CrCl < 30 mL/minute: 1mg/kg every 24 hours • Miscellaneous: • Avoid if CrCl is < 15mL/minute (use heparin) • Avoid if CABG is planned (longer t1/2)

  33. Fondaparinux (Arixtra®) • MOA: • Potentiates the inhibitory action of Antithrombin III (heparin cofactor) for inhibition of Factor Xa • Does not effect Factor IIa (no anticoagulant effect) • Contraindications: Active bleed, severe bleeding risk, serum creatinine > 3 mg/dL or CrCl < 30mL/minute • Recommendations: • STEMI: Patients undergoing fibrinolytic therapy (Class I) • NSTEMI: Patients undergoing invasive therapy (early or delayed) or conservative therapy (non-PCI) (Class I) • Dosing: • STEMI: 2.5mg IV bolus followed by 2.5mg SC once daily • NSTEMI: 2.5mg SC once daily • Miscellaneous: • Preferred if patient has high bleeding risk

  34. Bivalirudin (Angiomax®) • MOA: Direct (Reversible) Thrombin Inhibitor • Contraindications: Active bleed & severe bleeding risk • Recommendations: • STEMI: Patients undergoing PCI (Class I) • NSTEMI: Patients undergoing early evasive or delayed PCI (Class IIa) • Dosing: • STEMI: 0.75mg/kg IV bolus followed by 1.75mg/kg/hour • NSTEMI: 0.1mg/kg IV bolus followed by 0.25mg/kg/hour; when PCI is initiated, give 0.5mg/kg IV bolus followed by 1.75mg/kg/hour • Miscellaneous: • Option for patients with or history of HIT or high bleeding risk • Wait 30 minutes before administering if switching from UFH

  35. Thrombolytics or Tissue Plasminogen Activators (TPAs) • MOA: • Activates the endogenous fibrinolytic system by cleaving arginine-valine bond in plasminogen to produce plasmin • Plasmin in turn degrades fibrin clot, fibrinogen &plasma proteins • Overall effect: lyses of fibrin deposits (aka “clot busters”) • FDA Approved Products: • Alteplase (Activase®) • Reteplase (Retevase®) • Streptokinase (Streptase®) • Tenecteplase (Tnkase®)

  36. Thrombolytics or Tissue Plasminogen Activators (TPAs) • Contraindications: • Any prior intracranial hemorrhage • Known structural cerebrovascular lesions • Known intracranial malignant neoplasm • Ischemic stroke within past 3 months • Active bleeding • Significant closed head or facial trauma within 3 months • Recommendations: • STEMI: • Patients presenting with symptoms < 12 hours (Class I) • Patents presenting with symptoms 12-24 hours (Class IIa)

  37. Glycoprotein (GP) IIb/IIIa Inhibitors • MOA: • Inhibits platelet aggregation by reversibly binding to the platelet receptor GP IIB/IIIa, thus preventing the binding of fibrinogen and interfering platelet aggregation • FDA Approved Products: • Abciximab (Reopro®) • Eptifibatide (Integrilin®) • Tirofiban (Aggrastat®) • Contraindications: • Active bleeding, thrombocytopenia, prior stroke and renal dialysis (eptifibatide)

  38. Glycoprotein (GP) IIb/IIIa Inhibitors • Recommendations: • STEMI: • Patients undergoing primary PCI (Class IIa) • NSTEMI: • Patients undergoing primary PCI (Class I) • Patients without high risk and not undergoing PCI (Class IIb) • Miscellaneous: • Dosing is weight based • Renal dosing is applicable for eptifibatide & tirofiban

  39. Adjunctive Therapy • Nitroglycerin (NTG) • Decreases myocardial oxygen demands via venous (predominately) and arterial dilation • Recommended for all STEMI/NSTEMI patients with continuing ischemic discomfort • 0.4mg SL, repeated every 5 minutes times 3 doses • Beta Blockers • Decreases cardiac workload • Recommended for all STEMI/NSTEMI patients with 24 hours if not contraindicated • Target resting pulse rate 50-60 beats/minute • Metoprolol, propranolol, atenolol, carvedilol

  40. Adjunctive Therapy • Calcium Channel Blockers • Recommended for patients on max doses of Beta Blocker and NTG or those who are unable to tolerate a Beta Blocker • Continue to target resting pulse of 50-60 beats/minute • Diltiazem SR, verapamil SR, nifedipine SR or amlodipine • Aldosterone Antagonists • Recommended for patients with MI and ejection fraction (EF) < 40% and either DM or heart failure symptoms who are already receiving an ACE inhibitor • Spironolactone: Initial dose – 12.5mg/day with target of 25 - 50mg/day • Eplerenone: Initial dose – 25mg/day with target of 50mg/day

  41. Adjunctive Therapy • ACE Inhibitors • Recommended for all patients with heart failure, left ventricular dysfunction and EF < 40%, type 2 DM, or chronic kidney disease in the absence of contraindications • Captopril • Target dose: 50mg BID to TID • Enalapril: • Target dose: 10mg BID • Lisinopril: • Target dose: 10-20mg daily • Ramipril: • Target dose: 5mg BID or 10mg daily • Trandolapril: • Target dose: 4mg daily

  42. Adjunctive Therapy • Angiotensin Receptor Blockers (ARBs) • Patients with clinical signs of hear failure or left ventricular EF < 40% and with or without intolerant to an ACE inhibitor • Candesartan • Target dose: 32mg daily • Valsartan: • Target dose: 160mg twice daily • Statin Therapy • “Stabilizes” the “hot” plaque • Treatment of dyslipidemia (cardiovascular risk factor)

  43. Discharge Summary • Aspirin Therapy • Dose varies if PCI completed • Continue indefinitely • Clopidogrel/Prasugrel Therapy • Duration for 12 months and possibly up to 15 months • Statin Therapy • “stabilizes” the plaque and treatment of dyslipidemia • NTG Therapy • As needed for ischemic discomfort • Beta Blocker Therapy • Reduce cardiac workload & target heart rate of 50-60 beats/min. • Other Adjunctive Therapy as warranted • ACE/ARB • Aldosterone Antagonist

  44. STEMI Treatment Algorithm

  45. NSTEMI Treatment Algorithm

  46. NSTEMI Treatment Algorithm

  47. Objectives • Review Updated Guidelines for the Management of Coronary Artery Disease (CAD) • ACC/AHA STEMI and NSTEMI Guidelines • Review Key Drug Interactions Impacting CAD • Proton Pump Inhibitors (PPIs) & Clopidogrel • Review important FDA guidance Impacting CAD • Drug Safety Communication – Simvastatin 80mg

  48. Background • January 26, 2009, the FDA issued an “Early Communication” regarding the potential for certain PPIs to reduce the efficacy of clopidogrel • November 17, 2009, the FDA issued an informational document to health-care providers about an update to the Plavix label • Discussed the interaction of clopidogrel and omeprazole

  49. Interaction • Clopidogrel is metabolized to its active metabolite by the CYP450 system via multiple isoenzymes, with extensive action via the CYP2C19 • Omeprazole is a potent inhibitor of CYP2C19 • Providers should consider other CYP2C19 inhibitors when prescribing clopidogrel, which include: cimetidine, fluconazole, ketoconazole and fluoxetine (among others) • Label warns against using CYP2C19 inhibitors and specifically notes omeprazole

  50. Interaction • What about other PPI’s? • FDA recommendation specific about omeprazole (and esomeprazole) because of its potent inhibitory effect on CYP2C19 • Others have varying effect on CYP2C19

More Related